191 related articles for article (PubMed ID: 26197890)
21. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.
Body JJ; Diel IJ; Tripathy D; Bergstrom B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):299-302. PubMed ID: 16882128
[TBL] [Abstract][Full Text] [Related]
22. Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Yoshizawa H; Akimoto T; Nishino K; Inoue M; Ito C; Takeda S; Kotoda A; Tamba K; Yumura W; Muto S; Ueda Y; Kusano E
Clin Exp Nephrol; 2011 Aug; 15(4):567-71. PubMed ID: 21416249
[TBL] [Abstract][Full Text] [Related]
23. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection.
Pecherstorfer M; Ludwig H; Schlosser K; Buck S; Huss HJ; Body JJ
J Bone Miner Res; 1996 May; 11(5):587-93. PubMed ID: 9157773
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonate treatment recommendations for oncologists.
von Moos R
Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
[TBL] [Abstract][Full Text] [Related]
25. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Clemons M; Dranitsaris G; Ooi W; Cole DE
Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
[TBL] [Abstract][Full Text] [Related]
26. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
von Moos R; Caspar CB; Steiner R; Angst R; Inauen R; Schmieding K; Thürlimann B
Onkologie; 2010; 33(8-9):447-50. PubMed ID: 20838060
[TBL] [Abstract][Full Text] [Related]
27. Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
Luedders DW; Steinhoff J; Thill M; Rody A; Bohlmann MK
Anticancer Res; 2015 Mar; 35(3):1797-802. PubMed ID: 25750345
[TBL] [Abstract][Full Text] [Related]
28. Unusual Cause and Presentation of Collapsing Focal Segmental Glomerulosclerosis.
Bhat ZY; Sharma N; Pillai U; Singh A
Am J Ther; 2016; 23(3):e957-60. PubMed ID: 25420079
[TBL] [Abstract][Full Text] [Related]
29. [Clinical and pathological characteristics of focal segmental glomerulosclerosis in children].
Huang JP; Zhang JJ; Liu JC; Chen YN; Yao Y; Xiao HJ; Yang JY
Zhonghua Er Ke Za Zhi; 2004 Jul; 42(7):516-9. PubMed ID: 15324571
[TBL] [Abstract][Full Text] [Related]
30. [The role of ibandronate in the daily oncological practice].
Nagykálnai T
Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
[TBL] [Abstract][Full Text] [Related]
31. The first reported case of Atypical Femoral Fracture caused by daily ibandronate prescribed for bone metastases in breast cancer.
Espey R; Grimes S; Heyburn G; Kealey WD
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28487299
[TBL] [Abstract][Full Text] [Related]
32. Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications.
Migliorati CA; Armonis BN; Nicolatou-Galitis O
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jul; 106(1):e18-21. PubMed ID: 18585606
[TBL] [Abstract][Full Text] [Related]
33. Prednisone/cyclophosphamide treatment in adult-onset autosomal dominant familial focal segmental glomerulosclerosis (FSGS 1).
Grcevska L; Dzikova S; Petrusevska G; Polenakovic M
Clin Nephrol; 2006 Jun; 65(6):461-2. PubMed ID: 16792147
[No Abstract] [Full Text] [Related]
34. Collapsing Lesions and Focal Segmental Glomerulosclerosis in Pregnancy: A Report of 3 Cases.
Orozco Guillén OA; Velazquez Silva RI; Gonzalez BM; Becerra Gamba T; Gutiérrez Marín A; Paredes NR; Cardona Pérez JA; Soto Abraham V; Piccoli GB; Madero M
Am J Kidney Dis; 2019 Dec; 74(6):837-843. PubMed ID: 31378644
[TBL] [Abstract][Full Text] [Related]
35. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
36. A case of recurrent focal segmental glomerulosclerosis after kidney transplantation associated with variant conversion in the Columbia classification.
Unagami K; Kawanishi K; Shimizu T; Kanzawa T; Toki D; Okumi M; Omoto K; Horita S; Koike J; Honda K; Nagashima Y; Ishida H; Tanabe K; Nitta K
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():96-100. PubMed ID: 26031598
[TBL] [Abstract][Full Text] [Related]
37. Galactose therapy reduces proteinuria in patients with recurrent focal segmental glomerulosclerosis after kidney transplantation.
Robson K; Hill P; Langsford D; Dwyer K; Goodman D; Langham R
Nephrology (Carlton); 2015 Mar; 20 Suppl 1():13-6. PubMed ID: 25807852
[TBL] [Abstract][Full Text] [Related]
38. [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Jotterand V; Moll S; Martin PY; Saudan P
Nephrol Ther; 2009 Apr; 5(2):134-8. PubMed ID: 19013118
[TBL] [Abstract][Full Text] [Related]
39. [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Schivazappa C; Berto P; Baldini E; Barni S; Dauria G; Cortesi E
Recenti Prog Med; 2008 Jan; 99(1):27-31. PubMed ID: 18389868
[TBL] [Abstract][Full Text] [Related]
40. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS).
Canaud G; Dion D; Zuber J; Gubler MC; Sberro R; Thervet E; Snanoudj R; Charbit M; Salomon R; Martinez F; Legendre C; Noel LH; Niaudet P
Nephrol Dial Transplant; 2010 Apr; 25(4):1321-8. PubMed ID: 19773419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
